Vernakalant (INN; codenamed RSD1235 proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation. It was initially developed by Cardiome Pharma and the intravenous formulation was bought for further development by Merck in April 2009.
This page contains content from the copyrighted Wikipedia article "Vernakalant"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
